FDA: Ingredient Safety Decisions Under PCPSA Could Differ From CIR

Compared with the Cosmetic Ingredient Review, FDA could consider a wider selection of data in its ingredient safety evaluations under the Personal Care Products Safety Act, an FDA official says. Further, industry would have the burden of demonstrating reasonable certainty of no harm, a high bar to clear.